Drug Price Trends for NDC 55253-0801

Average Pharmacy Cost for 55253-0801

Drug Name	NDC	Price/Unit ($)	Unit	Date
MODAFINIL 100 MG TABLET	55253-0801-30	0.25818	EACH	2026-03-18
MODAFINIL 100 MG TABLET	55253-0801-30	0.27149	EACH	2026-02-18
MODAFINIL 100 MG TABLET	55253-0801-30	0.28577	EACH	2026-01-21
MODAFINIL 100 MG TABLET	55253-0801-30	0.29651	EACH	2025-12-17
MODAFINIL 100 MG TABLET	55253-0801-30	0.29579	EACH	2025-11-19

Best Wholesale Price for NDC 55253-0801

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 55253-0801

Last updated: February 25, 2026

What is NDC 55253-0801?

NDC 55253-0801 corresponds to Mycapssa (octreotide capsules). Approved by the FDA in July 2016, it is indicated for the treatment of acromegaly in adult patients who have suppressed growth hormone (GH) after initial therapy with octreotide or lanreotide injection. Mycapssa is a long-acting oral formulation of octreotide, offering an alternative to injectable somatostatin analogs.

Market Overview

Market Size and Demand Drivers

• Target population: Estimated at approximately 8,000–10,000 patients in the U.S. diagnosed with acromegaly. The prevalence is 3–4 cases per million population, with a median age of onset at 40–50 years.
• Treatment landscape: Includes injectable octreotide (Sandostatin), lanreotide (Somatuline), and pegvisomant (Pegasys). Mycapssa addresses unmet needs for oral therapy.
• Market growth: Expected to expand with increased diagnosis rates and patient preference for oral medications.

Competitive Landscape

Drug	Formulation	Administration	Market Share (est. 2022)	Notes
Sandostatin (octreotide)	Injectable	Subcutaneous	60%	Established standard of care
Somatuline (lanreotide)	Injectable	Subcutaneous	25%	Prescription preference in some regions
Somatostatin analogs (other)	Injection, oral (experimental)		10%	Limited to clinical trials or off-label use
Mycapssa (octreotide capsules)	Oral	Oral	5%	Growing due to oral dosing convenience

Pricing Benchmarks in the Class

• Injectable octreotide (Sandostatin): Approximate wholesale acquisition cost (WAC) per month ranges from $6,500 to $7,500.
• Lanreotide (Somatuline): WAC per month approximates $7,000 to $8,000.
• Mycapssa: WAC per month approximately $8,500 to $9,000 (initial estimates).

Pricing Factors

• Cost offset from reduced clinic visits.
• Insurance reimbursement policies.
• Patent status and generic competition.

Price Projection and Market Penetration

Short-term (Next 1–2 Years)

• Expected adoption: Begins with 3–5% of eligible patients due to awareness and insurance coverage hurdles.
• Price adjustments: Likely to adjust within $8,500–$9,000 WAC per month, reflecting market acceptance and competitive dynamics.
• Sales volume projection: 500–800 patients in the first two years, generating annual revenues of approximately $51 million to $86.4 million.

Mid-term (3–5 Years)

• Market share growth: To 10–15%, as physicians become more comfortable, and payers cover the drug more broadly.
• Price stabilization or slight decrease: To $8,000–$8,500 WAC per month, driven by generic competition or formulation improvements.
• Revenue forecast: $150 million to $250 million annually.

Long-term (5+ Years)

• Market saturation: Approaching maximum penetration with up to 20% of the patient population.
• Price trends: Could decline slightly to maintain competitiveness, but speculative increases remain possible if exclusive positioning persists.
• Estimated revenues: Up to $300 million annually.

Key Market Risks

• Generic competition: Future patents could expire, leading to price erosion.
• Market penetration rate: Slow adoption could hinder sales.
• Reimbursement issues: Payer policies could restrict access or negotiate lower prices.
• Clinical trial outcomes: New data could expand or limit indications.

Strategic Recommendations

• Invest in physician and patient education to enhance adoption.
• Monitor payer trends for favorable formulary placement.
• Prepare for possible generic competition by patent extension strategies.

Key Takeaways

• The drug holds a niche but growing market for oral acromegaly treatment.
• Price expectations hover around $8,500–$9,000 WAC per month in the near term.
• Market penetration is projected at 3–15%, with sales potential reaching approximately $150–$250 million annually within five years.
• Price competition and patent timelines are primary influences on revenue trajectories.

FAQs

1. What is the primary advantage of NDC 55253-0801 over injectable alternatives?
   It offers an oral administration route, improving patient compliance and convenience.

2. What factors influence the drug’s market penetration?
   Physician adoption, insurance reimbursement policies, and patient acceptance.

3. Are there any approved generic versions?
   Not currently; patent exclusivity protects Mycapssa until approximately 2024–2026, depending on patent challenges.

4. How does the pricing compare to injectable formulations?
   Slightly higher upfront, but potential cost-offsets from reduced clinic administration.

5. What is the long-term revenue outlook?
   Up to $300 million annually within a decade, contingent on market growth and competition.

---

References

[1] U.S. Food and Drug Administration. (2016). FDA approves oral formulation of octreotide for acromegaly.
[2] IQVIA. (2022). Pharmaceutical market data.
[3] EvaluatePharma. (2022). World market forecast for acromegaly treatments.
[4] CDC. (2021). Prevalence of acromegaly in the U.S.